Beyond scaled customers, our new logo additions from our ... In partnership with SAP, a global fashion brand increased its business with Vertex due to a global cloud transformation initiative.

Learn more about whether Open Text Corporation or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The ...

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Celonis was launched in 2011. The following year, the Munich-based company participated in SAP’s Startup Focus program — the starting point of a long-term business relationship between SAP and ...

T he past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX).The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

Revenue: US$666.8m (up 17% from FY 2023). Net loss: US$52.7m (loss widened by 303% from FY 2023). US$0.34 loss per share (further deteriorated from US$0.086 loss in FY 2023). Revenue was in line ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Continued momentum in the cloud business is driving SAP's top line growth. SAP outpaced its cloud revenue goals, with total cloud backlog, a key indicator of go-to-market success in cloud business ...